Performance of a multi-target, multi-cancer early detection (MCED) blood test in a prospectively collected cohort

Vladimir Gainullin,[1] Mael Manesse,[1*] Fanglei Zhuang,[1] Melissa Gray,[1] Hee Jung Hwang,[1*] Gustavo C. Cerqueira,[1*] Christopher L. Nobles,[1*] Madhav Kumar,[1] Kevin Arvai,[1*] Xi Chen,[1*] Christopher C. Tyson,[1] Chen Ji,[1*] Jin Bae,[1] Violeta Beleva Guthrie,[1*] Jaspreet Kaur,[1] Viatcheslav E. Katerov,[1] Larson Hogstrom,[1*] Leonardo Hagmann,[1*] Philip J. Uren,[2] Jorge Garces,[1] Hatim T. Allawi,[1] Vuna Fa,[1*] Abigail McElhinny,[1*] Gerard A. Silvestri,[3] David Chesla,[4] Robert W. Given,[5] Tomasz M. Beer,[1] Frank Diehl[2**]

[1]Exact Sciences Corporation, Madison, WI
[2]Exact Sciences Corporation, La Jolla, CA
[3]Medical University of South Carolina, Charleston, SC
[4]Corewell Health, Grand Rapids, MI
[5]Urology of Virginia, Virginia Beach, VA
*Former employee of Exact Sciences Corporation

**Corresponding Author
Frank Diehl, PhD
Senior Vice President, Research & Development, Multi-cancer Early Detection
Exact Sciences Corporation
11085 N. Torrey Pines Rd.
La Jolla, CA 92037
Email: fdiehl@exactsciences.com

Short title Multi-cancer early detection biomarkers in plasma

Keywords Multi-cancer early detection, cell-free DNA (cfDNA), methylation, proteins, mutations, reflex assay, machine learning

Abbreviations ASCEND-2, Ascertaining Serial Cancer patients to Enable New Diagnostic 2; cfDNA, cell-free DNA; CHIP, clonal hematopoiesis of indeterminate potential; CV, cross-validation; DETECT-A, Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing; ECL, electrochemiluminescence; gDNA, genomic DNA; LQAS, Long-probe Quantitative Amplified Signal; MCED, multi-cancer early detection; MDM, methylated DNA marker; MP, methylation and protein; MP-reflex, methylation and protein plus somatic mutation reflex; PCR, polymerase chain reaction; PPRLS, privacy-preserving record linkage; QC, quality control; ROC AUC, Receiver Operating Characteristic Area Under the Curve; SEER,

National Cancer Institute Surveillance, Epidemiology, and End Results; SoC, standard of care; TELQAS, Target Enrichment Long-probe Quantitative Amplified Signal; USPSTF, United States Preventive Services Taskforce

Abstract 290 words

Background:

Multi-target blood tests have the potential to detect a broad range of cancer types and stages. We previously trained and independently assessed the performance of four biomarker classes for cancer detection in a retrospectively assembled case-control feasibility study. The primary aim of this study was to assess the performance of a methylation and protein (MP) classifier using samples from a large, multi-center, prospectively collected case-control study. As part of the ongoing assay development process, we also performed an exploratory analysis investigating the addition of a somatic mutation reflex approach (MP-reflex) on samples with scores below the threshold for a positive MP call but above a clear negative MP call.

Methods:

This study included 6,352 samples (1,438 cancer and 4,914 non-cancer) representing all stages among 21 tumor organ types divided approximately equally between a training and a test set. The sensitivity of the MP classifier was determined at a high specificity. The MP-reflex approach was investigated on MP samples at the same specificity threshold and detectable MP signals above pre-specified lower thresholds.

Results:

At 98.5% specificity, the observed overall sensitivity for MP biomarkers was 50.9%, with sensitivities of 15.4%, 26.1%, 38.0%, 67.8%, 85.5%, and 37.5% for stages I, I and II combined, II, III, IV, and unknown, respectively. When breast and prostate cancers were excluded from the analysis, overall test sensitivity was 56.8%, with sensitivities of 17.2%, 30.7%, 48.6%, 73.5%, 86.5%, and 40.0% for stages I, I and II combined, II, III, IV, and unknown, respectively.

Conclusion:

Methylation and protein biomarkers detected all cancer organ types incorporated in the analysis, including those without standard of care (SoC) cancer screening options and aggressive cancers with poor 5-year survival. These results demonstrate the potential clinical validity of multi-biomarker testing for the detection of several cancer types.

Introduction

Cancer is the second leading cause of death in the U.S, with more than two million new cancer cases and over 618,000 cancer deaths projected to occur in 2025.[1] The United States Preventive Services Taskforce (USPSTF) recommends routine cancer screening for breast, colorectal, and cervical cancer in average risk individuals, and for lung cancer in individuals with elevated risk due to a pre-specified threshold exposure to tobacco.[2-5] Standard of care (SoC) cancer screening programs have improved mortality rates for these four cancers; however, two-thirds of annual cancer deaths are the result of cancers without endorsed screening.[1, 6]

Multi-cancer early detection (MCED) testing has the potential for earlier detection of multiple cancers simultaneously, including lower prevalence cancers and aggressive cancers (i.e. pancreatic, esophageal, liver, stomach, and ovarian) that are often detected at later stages.[1, 6] Advances in molecular and computational technologies have enabled the sensitive and specific detection of tumor-derived biomarkers in the blood. Most MCED assays currently in development utilize single biomarker classes, such as cell-free DNA (cfDNA) hyper-methylation,[7-14] mutations,[15] fragmentation patterns,[16-20] or proteins[21] to detect cancers. However, the utilization of single biomarker types may not account for the complexity and heterogeneity of cancer, particularly when tasked with detecting multiple cancers by a single test.[22] A combined, multi-target approach provides a more comprehensive assessment of shared cancer-associated biomarkers present in the blood, with the goal of improved sensitivity for early cancer detection.[23] To that end, MCED tests incorporating multi-biomarker classes are

also in development, utilizing DNA fragmentation and methylation with or without protein markers, or cfDNA mutation, aneuploidy, and methylation biomarkers, together with cancer-associated protein quantification.[24-29]

CancerSEEK was a multi-target MCED assay developed in a case-control setting and examined in a large prospective study and served as the foundation for subsequent test development. CancerSEEK (mutations and select proteins) was utilized in the Detecting cancers Earlier Through Elective mutation-based blood Collection and Testing (DETECT-A) study; the first prospective interventional clinical study to evaluate an MCED blood test. In DETECT-A, CancerSEEK detected 19% of stage I cancers, 15% of stage II cancers and 30% of stage III cancers at a specificity of 99%.[27] Using another initial version of CancerSEEK (mutations, proteins, and a machine learning classifier), Cohen et al., reported a sensitivity of 70% and a specificity of over 99% for eight types of cancer (ovary, liver, stomach, pancreas, esophagus, colorectal, lung, or breast) in a case-control feasibility study of 1005 patients.[24]

Douville *et al.* hypothesized that the test performance observed in the Cohen study could be improved by the addition of aneuploidy to the biomarker panel.[30] While maintaining a specificity of 99%, the combination of aneuploidy, cfDNA mutations, proteins, and a machine learning classifier detected seven cancer types (liver, ovary, pancreas, esophagus, stomach, colorectal, and lung); the sensitivity ranged from 77 to 97% and 38% for breast cancer. Using retrospectively assembled case-control feasibility study data, our group has also assessed MCED test performance utilizing DNA methylation and protein combinations,[31, 32] as well as 3-biomarker classes (methylation, aneuploidy, and proteins) and 4-biomarker classes (methylation, mutations, aneuploidy, and proteins) with a machine learning classifier.[25, 26] The aim of this study was to assess the performance of a two-biomarker (methylation and protein, MP) MCED assay using samples from a large, multi-center, prospectively collected case-control study. Aneuploidy was tested, but we did not include a performance assessment in this study (unpublished data). We also assessed the performance of a somatic mutation reflex approach in samples with initially

negative MP-results (MP-reflex) to test the feasibility of an MP-reflex assay in a high-throughput, reduced cost setting. We hypothesized that MP-reflex might be an efficient strategy to add a third biomarker class and enhance sensitivity for the detection of early-stage cancer.

Methods

Study Participants and Sample Collections

Ascertaining Serial Cancer patients to Enable New Diagnostic 2 (ASCEND-2), a multi-center, prospectively collected case-control study of clinically characterized participants, was the main source of the samples for this classifier development study. One hundred ninety sites within the United States (35 states) and 15 sites within Europe were engaged for subject enrollment. ASCEND-2 study included male and female subjects ≥50 years old with known cancer, suspicion of cancer, and controls without suspicion of cancer. Cancer cases had untreated primary malignancies confirmed through pathology reports and/or clinical/radiographic data. Subjects were excluded from the study if they had any previous cancer diagnosis within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers), or cancer recurrence within the study timeframe, or a concurrent diagnosis of multiple primary cancers. While free from suspicion of cancer at the time of enrollment, controls were not required to have completed all recommended cancer screening tests and were not followed contributing a blood sample to confirm the absence of cancer. All collection sites had Institutional Review Board approval, and all eligible subjects provided written informed consent and were assessed for study participation eligibility. Over 25,900 participants were enrolled in ASCEND-2, which included over 5,900 known cancer cases. A subset of these samples was selected to develop two different MCED cancer classifiers. Samples were selected based on plasma volume availability, clinical eligibility criteria, availability of validated clinical data prior to laboratory testing initiation, and demographic matching requirements between the training and test set cohorts. The number of cancers per organ site was targeted to represent cancers with high, common, and rare

146 incidence compared to adjusted National Cancer Institute Surveillance, Epidemiology, and End
147 Results (SEER) cancer incidence (accessed March 2024).[6] The number of cancers per stage
148 was targeted to be equal and not represent SEER to allow for data generation across all stages.
149 In order to meet these sample selection targets the ASCEND-2 enrollment was supplemented
150 with a set of 187 samples from a commercial vendor (Audubon Bioscience, Houston TX), and
151 12 cancer samples from an Exact Sciences study, Specimen Collection Study to Evaluate
152 Biomarkers (2021-05). Blood was collected in LBgard® tubes for plasma and buffy coat
153 extraction.
154
155 *Methylated DNA Marker (MDM) Analysis*
156 MDM candidates were identified from a genome-wide discovery approach using reduced
157 representation bisulfite sequencing of DNA extracted from frozen primary cancer tissues and
158 control tissues, in addition to normal buffy coat control samples. Candidate regions were
159 selected where there was differential hypermethylation between the cases and controls. MDM
160 candidates were then confirmed biologically on independent tissues before being tested on
161 archived plasma. The results of these marker selection and elimination studies were designed
162 primarily to remove non-discriminating biomarkers. Only the top performing MDMs across the
163 many different cancer studies were chosen for further evaluation as candidate methylation
164 markers for blood-based detection of cancer.[31, 33]
165 cfDNA was extracted from 6 mL plasma followed by bisulfite conversion on a Hamilton
166 Microlab STARlet (Hamilton Robotics, Reno, NV) using reagents manufactured by Exact
167 Sciences Corporation (Madison, WI). Bisulfite converted cfDNA was then analyzed using Target
168 Enrichment Long-probe Quantitative Amplified Signal (TELQAS™) chemistry.[31, 33] For the initial
169 target enrichment, converted cfDNA was transferred to a 96-well polymerase chain reaction
170 (PCR) plate and subjected to a multiplex PCR to amplify the MDMs and a reference methylation
171 marker. The PCR products were diluted 10-fold and evaluated in triplex or biplex assays using

172 Long-probe Quantitative Amplified Signal (LQAS™) on a Quantstudio 5 Dx Real-Time PCR
173 Instrument (Life Technologies Corporation, Grand Island, NY). TELQAS combines amplification
174 using real-time PCR and allele-specific detection of methylated target DNA through an invasive
175 cleavage assay.
176
177 *Protein Analysis*
178 Plasma protein concentrations were measured using commercially available assays for
179 select proteins on a Roche cobas e801 instrument (Roche Diagnostics, Indianapolis, IN) per
180 manufacturer recommendations.[33] The cobas e801 analyzer uses electrochemiluminescence
181 (ECL)-based immunoassays to measure protein concentrations.
182
183 *Mutation Analysis*
184 Select mutations (i.e. somatic variants associated with cancer) were assessed by
185 extracting cfDNA from ~10 mL of plasma followed by sequencing using a modified version of a
186 technology described by Cohen et al. 2021.[34] Genomic DNA (gDNA), extracted from the
187 matched buffy coat, was used for sequencing regions that were positive for mutations in cfDNA
188 to verify whether the detected mutations were attributable to clonal hematopoiesis of
189 indeterminate potential (CHIP). Only mutations detected in plasma but absent in the matched
190 buffy coat samples were considered tumor derived variants. Samples were subjected to quality
191 control (QC) based on sample-level, run-level, and control-level metrics. Sample counts and QC
192 failure modes were recorded. The MP and MP-reflex testing workflow is shown in Figure 2.
193
194 *Machine learning model development*
195 *MP classifier development*
196 Separate plasma aliquots were tested with the protein and methylation assays as
197 illustrated in Figure 2. Prior to classifier training, samples were partitioned into training (cross-

198 validation (CV), mini-hold-out) and test (hold-out test) sets (Figure 1). Only samples that passed
199 pre-specified methylation and protein assay quality control criteria were included in the training
200 process. The training set was used to select model architecture, feature engineering, and
201 transformation approaches as well as to perform hyperparameter tuning, and calibration of
202 specificity thresholds. MP classifier threshold calibration was performed on the CV set, with the
203 aim of achieving greater than or equal to 99.0% specificity while maintaining high sensitivity
204 within a mini-hold-out set (223 cancers; 985 non-cancers).

205 Machine learning was used to develop and train two individual binary (cancer or non-
206 cancer) classifiers for the methylation and protein panels, respectively (Figure 3a). The overall
207 methodology was as follows: 5-fold stratified CV partitions were generated using age bin (half-
208 decade), gender, ethnicity, race, cancer organ and stage as strata with the aim to produce
209 proportional train/validate partitions across folds. These static partitions were then used to
210 perform model selection across common linear and non-linear estimator architectures. Model
211 bias estimation was evaluated in comparison between train/validation performance using
212 sensitivity, specificity, total and partial Receiver Operating Characteristic Area Under the Curve
213 (ROC AUC) results. Model architecture with the least bias and highest performance was further
214 refined with hyper-parameter tuning and validation curve assessment. Robust model
215 parameters and thresholds were then locked before final model performance assessment using
216 the independent held-out test set.

217 After classifier development was completed, the individual methylation and protein
218 classifier results (cancer or non-cancer calls) were combined by an OR-logic overarching
219 classifier to generate the final classification status (positive or negative). OR-logic was selected
220 as the overarching MP classifier; other approaches (early and late fusion, weighted voting, and
221 logistic regression) did not offer significant advantages. The result was deemed positive when
222 either the methylation or protein assay provided a cancer-positive call. Hold-out test set samples
223 were evaluated using this final overarching OR-logic classifier configuration (Figure 3a).

224 *MP-reflex classifier development*

225 All samples were analyzed using the combined MP classifier described above. The MP-
226 reflex classifier training included 20 organ sites and all stages of cancer. Mutation classifier
227 thresholds were tuned using optimization in cross-validation within the training data set.
228 Samples were tested following the mutation assay workflow using plasma as well as the
229 corresponding buffy aliquots. The schematic of the different cancer classifiers that were
230 developed and tested is shown in Figure 3.

231 The mutation classifier consisted of three main components: variant-level artifact score,
232 CHIP, and sample-level aggregate mutation score that weighed evidence from variants passing
233 artifact and CHIP filter. The three components were developed using an independent sample
234 collection. The MP classifier was adapted to determine three outcomes (three-zone partitioning):
235 high-confidence cancer positive (red), high-confidence cancer negative (green), and signal that
236 fell between these two categories or zones (yellow; middle) (Figure 3b). Samples with high-
237 confidence scores were classified as cancer or non-cancer calls, respectively. Samples with MP
238 results that fell between high-confidence positive or high-confidence negative results (e.g.,
239 middle zone) underwent a follow up mutation assay evaluation. An OR logic model was chosen
240 as the overarching MP classifier.

241 For MP-reflex classifier training, mutation samples that failed QC and were in the middle
242 zone were considered negative (no variants) to avoid biasing the MP-reflex training results from
243 multiple mutation configuration versions to MP. MP and MP-reflex thresholds were calculated
244 using ROC curves in stratified cross-validation. Optimal thresholds across validation folds were
245 averaged, locked before testing and used for final performance estimation. The resulting
246 mutation classifier differentiated the outcome into a binary cancer or non-cancer call.

247 *Statistical analysis*

248 Sensitivity, specificity and binary classification thresholds were calculated using scikit-
249 learn metrics. 95% confidence intervals were calculated using binomial proportion Wilson score
250 method (statsmodels).

251 **Results**

252 **Participants and Sample Characteristics**

253 A total of 6,352 samples were selected from the ASCEND-2 study as well as two other
254 collections to develop and test a MP (Figure 1) as well as an MP-reflex cancer classifier (Figure
255 5). This overall set included 1,438 cancer participants across 21 organ sites and stages (anus
256 (n=28), bladder and urinary (n=65), breast (n=165), cervix uteri (n=22), colon and rectum
257 (n=161), esophagus (n=53), head and neck (squamous cell) (n=78), uterine (n=81), kidney
258 (n=80), lung and bronchus (n=348), pancreatic (n=76), prostate (n=66), small intestine (n=12),
259 liver and bile duct (n=50), stomach (n=58), ovary (n=37), thyroid (n=25), vulva (n=21), testis
260 (n=2), and hematologic malignancies (non-Hodgkin lymphoma (NHL; n=9) and multiple
261 myeloma; n=1) (Supplementary Materials Table 1). Non-cancer and cancer participants were
262 similar for age, sex, and race/ethnicity distributions (Table 1). The study recruited participants
263 that were broadly representative of the US population, with 81.7%, 13.0%, 12.9%, and 3.2%,
264 identifying as White, Hispanic/Latino, Black/African American, and Asian, respectively.
265 Specifically, based on the 2020 U.S. census rates and the FDA's 2020 clinical trial participation
266 rates,[35, 36] the Black/African American population was slightly overrepresented in both the
267 training and testing cohorts. The Hispanic/Latino ethnicity rate exceeded the clinical trial
268 participation rate; whereas the representation rate for Asian participants was slightly lower than
269 both the 2020 U.S. census and FDA 2020 clinical trial participation rates. Overall, the
270 race/ethnicity participation rates aligned with expectations for a classifier development study.

271 Cancer stages and organ sites in the training and test sets collectively represent more
272 than 80% of incident cancers observed in the general population.[1] The number of cancers per

273 organ site was targeted to represent cancers with high, common, and rare incidence compared
274 to adjusted SEER cancer incidence (accessed March 2024),[6] lung and bronchus cancers were
275 over-represented (SEER: 15.8% vs. 24.2% for ASCEND-2), while breast (17.7% vs. 11.5%),
276 prostate (17.5% vs. 4.6%), and hematological cancers were under-represented. The cancers
277 used for the classifier development by cancer organ type as shown in Supplementary Table 1.
278 Participant demographics for the analyzable MP training and test sets are shown in
279 Supplementary Table 2. Overall, cancer stage distributions within organ sites were
280 approximately equal for stages I-IV (27%, 21%, 26%, and 22% respectively) and ~3% with
281 unknown stage (Supplementary Figure 1).

282 **Methylation-Protein (MP) classifier training and testing**

283 *MP classifier interrogation*

284 The generalizability of the MP classifier was evaluated by comparing the performance of
285 the full training set (including the CV set and mini-hold-out set), the CV set alone, and the test
286 set. The full training set (n=3,027) and 5-fold cross-validation set (n=1,819) achieved 98.9%
287 (95% CI: 98.1-99.3%) and 98.8% (95% CI: 98.3-99.2%) specificity, respectively. The test set
288 (n=3,163) achieved 98.5% specificity (95% CI: 97.9-98.9%), with a false positive rate of 1.5%
289 (37/2432 non-cancer cases). No significant bias was observed between the full training set, CV
290 set, and test set performance by stage (Supplementary Figure 2) or specific tumor organ site
291 (Supplementary Figure 3).

292

293 *MP classifier test set performance*

294 The test set included 780 cancers and 2,534 non-cancers that were all tested using the
295 methylation and protein assays. A total of 28 (0.8%) samples failed pre-specified assay quality
296 control criteria. Fifty-seven samples from participants over 84 years of age (outside of the
297 intended use age range) were removed from the test set analysis. A 72-hour blood processing

298 window requirement was also applied to the test set cohort that resulted in the exclusion of an
299 additional 67 cases. MP classifier test set performance without age and blood processing
300 exclusions is shown in Supplementary Table 5. The set without these exclusions demonstrated
301 an overall sensitivity of 51.6% (95% CI: 48.0-55.1%) at a specificity of 98.4% (95% CI: 97.9-
302 98.9%).

303 The remaining analyzable MP sample set was 729 cancers and 2,434 non-cancers. The
304 MP classifier demonstrated an overall sensitivity of 50.9% (95% CI: 47.3-54.5%), and
305 sensitivities of 15.4% (95% CI: 10.9-21.3%), 26.1% (95% CI: 21.7-31.0%), 38.0% (95% CI:
306 30.9-45.7%), 67.8% (95% CI: 60.6-74.2%), 85.5% (95% CI: 79.4-90.0%) and 37.5% (95% CI:
307 22.9-54.7%) for stages I, I and II combined, II, III, IV, and unknown, respectively for 21 organ
308 types (Table 2). MP classifier performance was also assessed with breast and prostate cancers
309 excluded, with an observed overall sensitivity of 56.8% (95% CI: 52.8-60.7%), and sensitivities
310 of 17.2% (95% CI: 12.0-24.2%), 30.7% (95% CI: 25.4-36.6%), 48.6% (95% CI: 39.4-57.9%),
311 73.5% (95% CI: 66.0-79.9%), 86.5% (95% CI: 80.2-91.0%), and 40.0% (95% CI: 24.6-57.7%)
312 for stages I, I and II combined, II, III, IV, and unknown, respectively. Overall sensitivity excluding
313 cancer organ types with average-risk SoC screening (i.e. excluding breast, prostate, cervix
314 uteri, colon and rectum) was 54.8% (95% CI: 50.4-59.2%) and 63.7% (95% CI: 58.0-69.0%) for
315 the six most aggressive cancer organ types with the shortest 5-year survival rate[1] (i.e. pancreas,
316 esophagus, liver, lung and bronchus, stomach, and ovary). MP organ-specific performance
317 ranged from 11.8% (95% CI: 5.5-23.4%) for prostate to 80.0% (95% CI: 60.9-91.1%) for liver
318 and bile duct sites (Figure 4) and Table 3. Stage distributions for each organ type are provided
319 in Supplementary Table 3.

320 MP test set performance from all enrollment sites was also compared to the
321 performance from sites that were unique in the test set to determine if collection site influenced
322 the classifier performance. Thirty-one percent of test set samples (non-cancers n=597; cancers

n=383) were obtained from unique collection sites (n=71 sites) that were not included in the training set. The observed unique test set collection site overall sensitivity of 56.7% (95% CI: 51.7-61.5%) and 99.3% (95% CI: 98.3-99.7%) specificity were similar to the overall sensitivity and specificity observed for the full test set (sensitivity: 50.9% (95% CI: 47.3-54.5%); specificity 98.5% (95% CI: 97.9-98.9). Performance by stage was also similar between these test set cohorts (Supplementary Figure 4).

Methylation Protein (MP)- reflex classifier training and testing

MP-reflex classifier training

6,352 samples (1,438 cancers; 4,914 non-cancers) were utilized for the MP-reflex classifier development and testing as outlined in Figure 5. Participant demographic information for the analyzable MP-reflex classifier training and test sets is shown in Supplementary Table 4. Of the 3,038 samples pre-assigned to the training set, 3,027 analyzable samples (654 cancers; 2,373 non-cancers) were used to train the MP classifier as outlined above as well as for setting the lower bound classification between high-confidence negative and samples with middle zone results. The mutation classifier was trained on a subset of 931 (416 cancers and 515 non-cancers).

MP-reflex classifier test set performance

3,223 analyzable samples (746 cancers; 2,477 non-cancers) representing 20 organ types (stomach, ovary, prostate, colon and rectum, lung and bronchus, bladder and urinary, breast, head and neck (squamous cell), kidney, pancreas, uterus, esophagus, anus, vulva, liver and bile duct, small intestine, thyroid, cervix uteri, testis, Non-Hodgkin Lymphoma) and all stages were used to test the MP-reflex classifier (Figure 5). Multiple Myeloma was excluded from the analysis due to a small sample number (n=1). MP classifier resulted in 462 (299

348 cancers; 163 non-cancers) samples that fell into a “middle zone” (i.e., MP classifier results that
349 fell in-between confident positive and confident negative calls), and these samples were
350 analyzed using the mutations classifier.

351 By applying the tuned mutations thresholds, the MP-reflex classifier demonstrated a
352 specificity of 98.5% (95% CI: 97.9-98.9%), with an overall sensitivity of 55.2% (95% CI: 51.6-
353 58.8%), and sensitivities of 19.0% (95% CI: 14.0-25.3%), 29.5% (95% CI: 25.0-34.5%), 41.2%
354 (95% CI: 34.0-48.8%), 71.9% (95% CI: 65.0-77.9%), 89.4% (95% CI: 84.1-93.1%) and 46.9%
355 (95% CI: 30.9-63.6%) for stages I, I and II combined, II, III, IV, and unknown, respectively for all
356 20 organ types. The MP-reflex classifier performance was also assessed with breast and
357 prostate cancers excluded, with an observed overall sensitivity of 61.6% (95% CI: 57.6-65.3%),
358 and sensitivities of 21.9% (95% CI: 16.0-29.3%), 35.2% (95% CI: 29.6-41.2%), 52.7% (95% CI:
359 43.5-61.8%), 75.9% (95% CI: 68.7-81.9%), 90.8% (95% CI: 85.4-94.3%) and 51.7% (95% CI:
360 34.4-68.6%) for stages I, I and II combined, II, III, IV, and unknown, respectively. Overall
361 sensitivity excluding cancer organ types with average-risk SoC screening (i.e. excluding
362 breast, prostate, cervix, colon and rectum) was 59.9% (95% CI: 55.1-63.6%) and 66.9% (95%
363 CI: 61.4-71.9%) for the six most aggressive cancer organ types with the shortest 5-year
364 survival rate[1] (i.e. pancreas, esophagus, liver, lung and bronchus, stomach, and ovary) (Table
365 4).

366

367 *MP and MP-reflex classifier performance comparison*

368 MP and MP-reflex classifier performance were compared using the MP-reflex test set
369 (746 cancers and 2,477 non-cancers). At specificities of ≥98.5%, the MP-reflex classifier
370 showed absolute sensitivity (absolute change%=MP-reflex sensitivity% minus MP sensitivity%)
371 increases of 3.8%, 3.1%, 2.4%, 1.1%, and 2.7%, for stages I, I and II combined, II, III, and IV,
372 respectively, compared to the MP classifier. The overall absolute sensitivity gain of the MP-
373 reflex classifier was 2.8% (5.3% relative gain; defined as MP-reflex sensitivity% minus MP

374 sensitivity% divided by MP sensitivity% x 100) compared to the MP classifier sensitivity.
375 Notably, the absolute sensitivity gain of the MP-reflex classifier for early stages (stages I and II)
376 was 3.1% (11.7% relative gain) compared to the MP classifier (Figure 6). The relative gain in
377 sensitivity was greatest in stage I disease at 25.0%.

378 MP and MP-reflex classifier performance was also compared for cancer organ types with
379 average-risk standard of care screening (i.e., excluding breast, prostate, cervix, colon and
380 rectum). The 59.4% (95% CI: 55.1-63.6%) observed overall sensitivity for the MP-reflex
381 classifier represents a 2.8% absolute increase compared to the MP classifier (56.6%, 95% CI:
382 52.3-60.9%). Additionally, the 66.9% (95% CI: 61.4-71.9%) overall sensitivity observed for the
383 MP-reflex classifier represents a 2.0% absolute increase for the six most aggressive cancer
384 organ types (pancreatic, esophagus, liver, lung, stomach, and ovarian) compared to the MP
385 classifier (64.9%, 95% CI: 59.5-70.1%). The relative sensitivity gain was 23.0% for stage I and
386 4.6% for stage II in this subgroup.

387

388 **Discussion**

389 Building upon our previous efforts in MCED assay development, we evaluated the
390 performance of two different multi-target biomarker configurations in a large, multi-center
391 prospectively collected case-control study. The ASCEND-2 study included a racially, ethnically,
392 and geographically diverse sample representative of the U.S. population.[35] Age, sex, and
393 race/ethnicity were comparable between the cancer and non-cancer groups in both the training
394 and test sets. Organ sites and cancer stages (which were approximately equally distributed)
395 collectively represent most incident cancers observed in the U.S. population, including
396 aggressive cancers and cancers without guideline-recommended screening options.
397 We have previously reported case-control study feasibility data for three (methylation, protein,
398 aneuploidy) and four biomarker classes (methylation, protein, aneuploidy, and mutations)
399 MCED assay configurations across fifteen organ sites. In this early detection biomarker

400 feasibility work, the observed overall sensitivities were 53.4% and 61.0% at specificities of
401 98.8% and 98.2% for the combined three or four biomarker classes, respectively.[25] We then
402 refined and optimized each biomarker algorithm as well as the overarching cancer classifier,
403 resulting in improved overall sensitivities of 55.2% and 62.4% at specificities of 99.0% and
404 98.0% for the combined three or four biomarker classes, respectively.[26]

405 Based on individual biomarker contributions to overall performance, in this study we
406 initially focused on a combined MP assay configuration in an ongoing effort to increase assay
407 efficiency while maintaining sensitivity and specificity. The MP assay classifier demonstrated an
408 overall sensitivity of 50.9%, which was comparable to the overall sensitivities reported above for
409 the three biomarkers (methylation, protein, aneuploidy) MCED assay configuration while
410 maintaining a high specificity of 98.5%. Measuring cfDNA-based biomarkers for breast and
411 prostate cancers is particularly challenging due to nominal circulating tumor DNA shedding
412 rates associated with low tumor burden and high variability in circulating tumor DNA due to
413 tumor heterogeneity.[37-39] Further, these two cancers have established high-performing
414 screening options. The overall sensitivity of MP performance with breast and prostate cancers
415 excluded was 56.8%.

416 MCED tests currently in development are intended to complement, not replace, SoC
417 cancer screening modalities. Interestingly, when cancer organ types with average-risk SoC
418 screening were excluded except for lung cancers, which do not have a screening option for the
419 general population (i.e., excluding breast, prostate, cervix, colon and rectum), the MP classifier
420 demonstrated an overall sensitivity of almost 55%. In addition, overall sensitivity was nearly
421 64% for the six most aggressive cancer types with the shortest 5-year survival. Although
422 preliminary, these data suggest that MCED tests may broaden population wide screening
423 availability for individuals who are not adherent with current screening programs and for those
424 with cancers without SoC screening options.

425 To further enhance cancer detection, particularly for stage I and II cancers, without
426 substantially increasing testing complexity and cost, a second three-biomarker class approach
427 was also explored. In this approach, methylation and protein testing are performed on all
428 samples first followed by mutation testing for a fraction of samples that were neither highly
429 positive nor negative for the methylation and protein biomarkers. By interrogating the mutation
430 profiles of tumor hotspots for MP "middle zone" samples, the MP-reflex approach demonstrated
431 a sensitivity increase of 3.1% (11.7% relative gain) for stage I and II cancers while maintaining a
432 specificity of 98.5%. The greatest relative improvement in sensitivity was observed for the
433 detection of stage I cancers. While we achieved modest improvements for stage I and II
434 detection with the reflex approach; early-stage sensitivities were lower than those observed for
435 recommended single cancer screening tests that directly interrogate the organ of interest at
436 lower specificities. Sensitivity improvements were also observed when cancer types with
437 average risk SoC screening were considered (2.8% absolute increase for MP-reflex, data not
438 shown) and for the six most aggressive cancer types (3.0% absolute increase for MP-reflex).
439 In addition to the enhanced performance exhibited by the MP-reflex classifier for early-
440 stage cancer detection, the reflex methodology is also more cost-effective compared to
441 conducting methylation, protein, and mutation testing simultaneously on all samples. The MP
442 classifier result triggered the reflex mutations testing in about 16% of the test set samples ,
443 achieving a favorable balance between improved early-stage sensitivity and reduced assay
444 cost. Reduction in assay cost is critical to support the ability to deliver a widely accessible assay
445 for all those who might benefit from MCED screening.
446
447 **Limitations**
448 Case-control studies like ASCEND-2 are an efficient data source for classifier training
449 and assessing classifier performance in an independent hold-out test cohort. As with any case-
450 control study, the approach applied here has limitations. First, ASCEND-2 enrollment

451 criteria for the non-cancer control cohort depended on self-reported and recorded information to
452 define cancer-free status just prior to or at the time of enrollment. Full adherence with
453 recommended cancer screening was not required. Also, ASCEND-2 did not have a pre-defined
454 built in longitudinal follow up included that would allow us to identify any cancer that developed
455 within a one-to-two-year timeframe from the time of the blood draw. Therefore, the training and
456 test cohorts likely included unobserved cancer or pre-cancers that could have resulted in a
457 cancer-related biomarker signal. Approximately 1% of individuals above the age of 50 (almost
458 1.8 million individuals estimated in 2025) are diagnosed with cancer each year.[40] Thus,
459 undiagnosed cancers are expected in the general population. For screening tests with a high
460 specificity that aim for no more than 1.5% false positive results, this level of undiagnosed cancer
461 burden represents a challenge. This would have complicated the training process as well as the
462 interpretation of the testing results. One approach in the future is to further evaluate these
463 results by utilization of privacy-preserving record linkage (PPRLS) techniques (i.e., tokenization)
464 to determine subsequent cancer status by linking participant data sets from electronic medical
465 records with results from the non-cancer test cohort.

466 Second, the enrollment of cancer participants in ASCEND-2 was not limited to a single
467 diagnostic pathway that would be reflective of an asymptomatic screening test user. Specifically,
468 the ASCEND-2 cancer cohort participants were identified by one of these mechanisms:
469 screening, incidental findings, or by symptoms. It is expected, depending on this diagnostic
470 enrollment mechanism, that there are differences in biomarker signal strength and distribution.
471 Depending on the cancer type and stage, the ratio between these three pathways could
472 fluctuate and may not reflect the diagnostic pathways in a screening setting.

473 ASCEND-2 study enrollment was enriched for lung and bronchus cancer, while breast,
474 prostate, and hematological cancers were under-represented. This may have influenced
475 performance results as sensitivities vary widely across individual cancer types. Disproportionate
476 over-sampling of specific cancer types with higher sensitivities (lung and bronchus) while under

477 sampling those with lower sensitivities (breast, prostate) would be expected to result in higher
478 overall sensitivities. In addition, we targeted equal stage distribution across all the cancer types
479 included in ASCEND-2. Consequently, compared to SEER incidence, a higher number of later-
480 stage cancers were included in the study.

481 Third, the prospectively collected ASCEND-2 included a diverse population; however,
482 the analyses were performed in a case-control fashion without the return of results to
483 participants. Reported MCED test sensitivities have been higher for case–control studies
484 (70.0% overall sensitivity for Cohen's CancerSEEK case–control study) compared to
485 prospective studies (27.1% overall sensitivity) observed in DETECT-A.[24, 27] Prospective clinical
486 validation studies in average risk individuals will reflect assay and clinical diagnostic work-up
487 performance in the intended-use population.

488 Finally, reporting of test performance in subsets of the study population defined by age,
489 gender, race, ethnicity, risk factors for cancer and other factors of interest is beyond the scope
490 of this report owing the small sample size available for such analyses. Future research will be
491 needed to further evaluate test performance in subsets of the overall population.

492

493 **Conclusion**

494 MP and MP-reflex classifier strategies resulted in overall sensitivities of 50.9% and
495 55.2% for a broad range of cancers respectively, at a specificity of 98.5%. These results
496 represent a progress report from an ongoing program developing a multi-biomarker class MCED
497 test.

498 A real-world evidence registry, Falcon (Clinical Trial Identifier: NCT06589310) was
499 initiated in 2024 to prospectively investigate test performance and the uptake, diagnostic
500 journey, adherence with guideline-recommended cancer screening, outcomes, and
501 psychological impacts of MCED testing.

Acknowledgements

The authors would like to thank the following individuals: Jing Tong, Amira Best, David Sims, Jeremy Thorpe, Christopher Gault, Farhad Hatami and Mark Evans for feedback on study design and execution, sample processing and data preparation, Natsuyo Aoyama for project management support, Fikrullah Kisa, Peter Ngam, Jerry Machado and Raja Kakuturu for wet laboratory leadership, Amy Lehman for statistical analysis and Amin Mazloom (Exact Sciences Corporation, Madison, WI) for leadership and feedback. Carolyn Hall and Feyza Sancar (Exact Sciences Corporation, Madison, WI) provided manuscript writing and editorial support. The authors would also like to thank the patients who generously participated in the original sample collection studies and the principal investigators and institutions who oversaw their enrollment.

Author Contributions

Conceptualization: Frank Diehl

Methodology: Vladimir Gainullin, Frank Diehl

Formal Analysis: Vladimir Gainullin, Mael Manesse, Fanglei Zhuang, Melissa Gray, Hee Jung Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Madhav Kumar, Kevin Arvai, Xi Chen, Christopher Tyson, Chen Ji, Jin Bae, Violeta Beleva Guthrie, Jaspreet Kaur, Viatcheslav E. Katerov, Larson Hogstrom, Leonardo Hagmann, Philip J. Uren, Vuna Fa, Abigail McElhinny

Investigation: Gerard Silvestri, David Chesla, Robert Given

Writing-Original Draft: Vladimir Gainullin, Frank Diehl, Tomasz M. Beer

Writing-Review and Editing: Vladimir Gainullin, Mael Manesse, Fanglei Zhuang, Melissa Gray, Hee Jung Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Madhav, Kumar, Kevin Arvai, Xi Chen, Chris Tyson, Chen Ji, Jin Bae, Violeta Beleva Guthrie, Jaspreet Kaur, Viatcheslav E. Katerov, Larson Hogstrom, Leonardo Hagmann, Philip Uren, Jorge Garces, Hatim T. Allawi,

Vuna Fa, Abigail McElhinny, Gerard Silvestri, David Chesla, Robert Given, Tomasz M. Beer, Frank Diehl

Project Administration: Jorge Garces, Hatim T. Allawi, Tomasz M. Beer, Frank Diehl

Funding

This work was funded by Exact Sciences Corporation.

Disclosures

Mael Manesse, Hee Jung Hwang, Gustavo C. Cerqueira, Christopher L. Nobles, Kevin Arvai, Xi Chen, Chen Ji, Violeta Beleva Guthrie, Larson Hogstrom, Leonardo Hagmann, Vuna Fa, and **Abigail McElhinny** were employed at Exact Sciences Corporation at the time of study execution and report stock ownership at Exact Sciences Corporation. **Mael Manesse** reports employment at Nomic Bio; and stock ownership at Ultivue Inc. **Hee Jung Hwang** reports employment at Quest Diagnostics. **Gustavo C. Cerqueira** reports employment and stock ownership at NeoGenomics. **Christopher L. Nobles** and **Violeta Beleva Guthrie** report employment and stock ownership at Natera Inc; and advisory/consulting roles at AOA Dx. **Christopher L. Nobles** reports an advisory/consulting role at Universal Diagnostics. **Larson Hogstrom** reports employment and stock ownership at Merck. **Vuna Fa** reports employment at AOA Dx. **Abigail McElhinny** reports a former leadership role at Exact Sciences Corporation; and employment, leadership, and stock ownership at AOA Dx.

Vladimir Gainullin, **Fanglei Zhuang**, **Melissa Gray**, **Madhav Kumar**, **Christopher C.Tyson**, **Jin Bae**, **Jaspreet Kaur**, **Viatcheslav E. Katerov**, **Philip J. Uren**, **Jorge Garces**, **Hatim T. Allawi**, **Tomasz M. Beer**, and **Frank Diehl** are employees at Exact Sciences Corporation and report stock ownership at Exact Sciences Corporation. **Jorge Garces**, **Hatim T. Allawi**, **Tomasz M. Beer**, and **Frank Diehl** hold leadership roles at Exact Sciences Corporation. **Philip J. Uren** reports stock ownership at Biora Therapeutics. **Jin Bae** reports royalty interests from Pacific Bioscience managed by The Broad Institute. **Tomasz M. Beer** reports stock ownership at Osteologic and Osheru; and a consulting/advisory role at AstraZeneca. **Gerard A. Silvestri** reports advisory board service at Candel Therapeutics; consulting fees from Freenome and Biodesix; and research funding (Institutional) from NIH (RO1 screening in frail populations), Nucleix, Inc, Biodesix, Delfi Diagnostics, and Freenome. **Gerard A. Silvestri** serves on the American Cancer Society roundtable steering committee. **David Chesla** reports no conflict of interest. **Robert W. Given** reports speakers' bureau service at Bayer, and Johnson & Johnson; research funding from Francis Medical, MDX Health, Levee, and Dendreon; and travel reimbursement from Francis Medical.

561 **References**

562 1 Siegel RL, Kratzer TB, Giaquinto AN et al. Cancer statistics, 2025. CA Cancer J Clin
563 2025; 75 (1): 10-45.

564 2 Curry SJ, Krist AH, Owens DK et al. Screening for Cervical Cancer: US Preventive
565 Services Task Force Recommendation Statement. JAMA 2018; 320 (7): 674-686.

566 3 Davidson KW, Barry MJ, Mangione CM et al. Screening for Colorectal Cancer: US
567 Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19):
568 1965-1977.

569 4 Potter AL, Bajaj SS, Yang CJ. The 2021 USPSTF lung cancer screening guidelines: a
570 new frontier. Lancet Respir Med 2021; 9 (7): 689-691.

571 5 Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force
572 Recommendation Statement. Ann Intern Med 2016; 164 (4): 279-296.

573 6 SEER Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance
574 Research Program, National Cancer Institute (2023).[Accessed March 4,
575 2024].https://seer.cancer.gov/statistics-network/explorer/

576 7 Chen X, Dong Z, Hubbell E et al. Prognostic Significance of Blood-Based Multi-cancer
577 Detection in Plasma Cell-Free DNA. Clinical Cancer Research 2021; 27 (15): 4221-
578 4229.

579 8 Chen X, Gole J, Gore A et al. Non-invasive early detection of cancer four years before
580 conventional diagnosis using a blood test. Nat Commun 2020; 11 (1): 3475.

581 9 Gao Q, Lin YP, Li BS et al. Unintrusive multi-cancer detection by circulating cell-free
582 DNA methylation sequencing (THUNDER): development and independent validation
583 studies. Ann Oncol 2023; 34 (5): 486-495.

584 10 Kandimalla R, Xu J, Link A et al. EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint
585 for the Early Detection of Gastrointestinal Cancers. Clin Cancer Res 2021; 27 (22):
586 6135-6144.

587 11 Klein EA, Richards D, Cohn A et al. Clinical validation of a targeted methylation-based
588 multi-cancer early detection test using an independent validation set. Ann Oncol 2021;
589 32 (9): 1167-1177.
590 12 Liu MC, Oxnard GR, Klein EA et al. Sensitive and specific multi-cancer detection and
591 localization using methylation signatures in cell-free DNA. Ann Oncol 2020; 31 (6): 745-
592 759.
593 13 Schrag D, Beer TM, McDonnell CH, 3rd et al. Blood-based tests for multicancer early
594 detection (PATHFINDER): a prospective cohort study. Lancet 2023; 402 (10409): 1251-
595 1260.
596 14 Shen SY, Singhania R, Fehringer G et al. Sensitive tumour detection and classification
597 using plasma cell-free DNA methylomes. Nature 2018; 563 (7732): 579-583.
598 15 Ris F, Hellan M, Douissard J et al. Blood-Based Multi-Cancer Detection Using a Novel
599 Variant Calling Assay (DEEPGEN(TM)): Early Clinical Results. Cancers (Basel) 2021;
600 13 (16): 4104.
601 16 Bao H, Wang Z, Ma X et al. Letter to the Editor: An ultra-sensitive assay using cell-free
602 DNA fragmentomics for multi-cancer early detection. Mol Cancer 2022; 21 (1): 129.
603 17 Cristiano S, Leal A, Phallen J et al. Genome-wide cell-free DNA fragmentation in
604 patients with cancer. Nature 2019; 570 (7761): 385-389.
605 18 Helzer KT, Sharifi MN, Sperger JM et al. Fragmentomic analysis of circulating tumor
606 DNA-targeted cancer panels. Ann Oncol 2023; 34 (9): 813-825.
607 19 Zhou X, Zheng H, Fu H et al. CRAG: de novo characterization of cell-free DNA
608 fragmentation hotspots in plasma whole-genome sequencing. Genome Med 2022; 14
609 (1): 138.
610 20 Bao H, Yang S, Chen X et al. Early detection of multiple cancer types using
611 multidimensional cell-free DNA fragmentomics. Nat Med 2025.

612 21 Bogdan B, Hossein A, Mohammad HF, Ashkan A. Novel proteomics-based plasma test
613 for early detection of multiple cancers in the general population. BMJ Oncology 2024; 3
614 (1): e000073.
615 22 Ahlquist DA. Universal cancer screening: revolutionary, rational, and realizable. NPJ
616 Precis Oncol 2018; 2: 23.
617 23 Kisiel JB, Ebbert JO, Taylor WR et al. Shifting the Cancer Screening Paradigm:
618 Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing.
619 Life 2024; 14 (8): 925.
620 24 Cohen JD, Li L, Wang Y et al. Detection and localization of surgically resectable cancers
621 with a multi-analyte blood test. Science 2018; 359 (6378): 926-930.
622 25 Douville C, Nobles C, Hwang HJ et al. 73P Multi-cancer early detection through
623 evaluation of aneuploidy, methylation, and protein biomarkers in plasma. Annals of
624 Oncology 2022; 33: S575.
625 26 Gianullin V, Hagmann L, Arvai K et al. Abstract P041: Improved sensitivity of a multi-
626 analyte early detection test based on mutation, methylation, aneuploidy, and protein
627 biomarkers. Cancer Prevention Research 2023; 16 (1_Supplement): P041-P041.
628 27 Lennon AM, Buchanan AH, Kinde I et al. Feasibility of blood testing combined with PET-
629 CT to screen for cancer and guide intervention. Science 2020; 369 (6499): eabb9601.
630 28 Putcha G, Liu T-Y, Ariazi E et al. Blood-based detection of early-stage colorectal cancer
631 using multiomics and machine learning. Journal of Clinical Oncology 2020; 38 (4_suppl):
632 66-66.
633 29 Yang Z, LaRiviere MJ, Ko J et al. A Multianalyte Panel Consisting of Extracellular
634 Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and
635 Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020; 26 (13): 3248-
636 3258.

637 30 Douville C, Cohen JD, Ptak J et al. Assessing aneuploidy with repetitive element
638 sequencing. Proc Natl Acad Sci U S A 2020; 117 (9): 4858-4863.
639 31 Allawi HT, Katerov S, Vaccaro A et al. Abstract 631: Validation of a panel of methylated
640 DNA and protein markers for multi-cancer detection in plasma. Cancer Research 2022;
641 82 (12_Supplement): 631-631.
642 32 Katerov VE, Fleming HL, Rugowski DE et al. The detection of multiple cancer types with
643 an extended set of methylation and protein markers. Journal of Clinical Oncology 2023;
644 41 (16_suppl): 3040-3040.
645 33 Katerov S, Vaccaro A, Hennek J et al. Abstract 111: Accurate multi-cancer detection
646 using methylated DNA markers and proteins in plasma. Cancer Research 2021; 81
647 (13_Supplement): 111-111.
648 34 Cohen JD, Douville C, Dudley JC et al. Detection of low-frequency DNA variants by
649 targeted sequencing of the Watson and Crick strands. Nat Biotechnol 2021; 39 (10):
650 1220-1227.
651 35 U.S. Census Bureau 2020. Profile of General Population and Housing
652 Characteristics.[Accessed may 2,
653 2025].https://data.census.gov/table?g=010XX00US&d=DEC+Demographic+Profile
654 36 United States Food and Drug Administration. 2020 Drug Trail Snapshorts.[Accessed
655 March 9, 2025]. https://www.fda.gov/media/145718/download
656 37 Brito-Rocha T, Constancio V, Henrique R, Jeronimo C. Shifting the Cancer Screening
657 Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
658 Cells 2023; 12 (6).
659 38 Dao J, Conway PJ, Subramani B et al. Using cfDNA and ctDNA as Oncologic Markers:
660 A Path to Clinical Validation. International Journal of Molecular Sciences 2023; 24 (17):
661 13219.

39 He W, Xiao Y, Yan S et al. Cell-free DNA in the management of prostate cancer: Current status and future prospective. Asian Journal of Urology 2023; 10 (3): 298-316.

40 American Cancer Society. Cancer Facts & Figures 2025. Atlanta, GA; 2025.[Accessed March 5, 2025]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf

683 Table 1. Participant demographics for classifier development

Variable		Non-Cancer (4914)	Cancer (1438)	Total (6352)
Sex	Female	2799 (57.0%)	776 (54.0%)	3575 (56.3%)
	Male	2115 (43.0%)	662 (46.0%)	2777 (43.7%)
Age (years)	Mean (SD)	65.1 (8.1)	66.9 (9.0)	65.5 (8.3)
	(Min, Max)	(50, 101)	(50, 92)	(50, 101)
Race	American Indian or Alaska Native	20 (0.4%)	9 (0.6%)	29 (0.5%)
	Asian	145 (3.0%)	58 (4.0%)	203 (3.2%)
	Black or African American	698 (14.2%)	119 (8.3%)	817 (12.9%)
	Mixed Race	11 (0.2%)	2 (0.1%)	13 (0.2%)
	Native Hawaiian or Other Pacific Islander	5 (0.1%)	1 (0.1%)	6 (0.1%)
	Unknown/Missing	39 (0.8%)	56 (3.9%)	95 (1.5%)
	White	3996 (81.3%)	1193 (83.0%)	5189 (81.7%)
Ethnicity	Hispanic/Latino	748 (15.2%)	80 (5.6%)	828 (13.0%)
	Not Hispanic/Latino	4135 (84.1%)	1308 (91.0%)	5443 (85.7%)
	Unknown/Missing	31 (0.6%)	50 (3.5%)	81 (1.3%)

684
685
686
687
688
689
690
691
692
693
694

695 Table 2. MP classifier test set performance

	Performance (95% CI)	**n/N**
Specificity	98.5% (97.9-98.9)	2,397/2,434
Overall Sensitivity, all cancers	50.9% (47.3-54.5)	371/729
Stage I	15.4% (10.9-21.3)	28/182
Stage II	38.0% (30.9-45.7)	62/163
Stage III	67.8% (60.6-74.2)	122/180
Stage IV	85.5% (79.4-90.0)	147/152
Unknown Stage	37.5% (22.9-54.7)	12/32
Stages I/II	26.1% (21.7-31.0)	90/345
Overall Sensitivity, breast and prostate cancers excluded	56.8% (52.8-60.7)	335/590
Stage I	17.2% (12.0-24.2)	25/145
Stage II	48.6% (39.4-57.9)	53/109
Stage III	73.5% (66.0-79.9)	111/151
Stage IV	86.5% (80.2-91.0)	134/155
Unknown Stage	40.0% (24.6-57.7)	12/30
Stages I/II	30.7% (25.4-36.6)	78/254
Overall Sensitivity*	54.8% (50.4-59.2)	268/489
Overall Sensitivity**	63.7% (58.0-69.0)	186/292

696

697 MP, methylation-protein.*sensitivity excluding cancer organ types with average-risk standard of
698 care screening (i.e., excluding breast, prostate, cervix, colon and rectum). **sensitivity for the 6
699 most aggressive cancer organ types with the shortest 5-year survival rate reported by National
700 Cancer Institute Surveillance, Epidemiology, and End Results (SEER) (i.e., pancreas,
701 esophagus, liver, lung and bronchus, stomach, and ovary).

702

703

704

705

706

707

708 Table 3. MP classifier test set sensitivity by organ type and stage

Organ Type	Sensitivity (95% Confidence Interval)				
	Stage I	Stage II	Stage III	Stage IV	Unknown Stage
Lung and Bronchus (n=159)	13% (6.1%, 25.7%) n=46	52.2% (33%, 70.8%) n=23	77.1% (63.5%, 86.7%) n=48	92.3% (79.7%, 97.3%) n=39	100% (43.9%, 100%) n=3
Breast (n=88)	8.3% (2.3%, 25.8%) n=24	30% (16.7%, 47.9%) n=30	47.8% (29.2%, 67%) n=23	88.9% (56.5%, 98%) n=9	0% (0%, 65.8%) n=2
Colon and Rectum (n=88)	15.4% (4.3%, 42.2%) n=13	50% (29%, 71%) n=18	76% (56.6%, 88.5%) n=25	92.6% (76.6%, 97.9%) n=27	40% (11.8%, 76.9%) n=5
Prostate (n=51)	7.7% (1.4%, 33.3%) n=13	0% (0%, 13.8%) n=24	0% (0%, 39%) n=6	62.5% (30.6%, 86.3%) n=8	
Uterus (n=39)	15% (5.2%, 36%) n=20	25% (4.6%, 69.9%) n=4	57.1% (25%, 84.2%) n=7	83.3% (43.6%, 97%) n=6	0% (0%, 65.8%) n=2
Pancreas (n=37)	42.9% (15.8%, 75%) n=7	50% (21.5%, 78.5%) n=8	100% (64.6%, 100%) n=7	92.9% (68.5%, 98.7%) n=14	0% (0%, 79.4%) n=1
Head and Neck (n=36)	40% (16.8%, 68.7%) n=10	40% (11.8%, 76.9%) n=5	54.5% (28%, 78.7%) n=11	80% (49%, 94.3%) n=10	
Kidney (n=32)	O% (0%, 29.9%) n=9	50% (15%, 85%) n=4	25% (4.6%, 69.9%) n=4	81.8% (52.3%, 94.9%) n=11	0% (0%, 49%) n=4
Stomach (n=30)	20% (3.6%, 62.4%) n=5	57.1% (25%, 84.2%) n=7	85.7% (48.7%, 97.4%) n=7	100% (70.1%, 100%) n=0	50% (9.5%, 90.5%) n=2

Bladder and Urinary (n=28)	14.3% (2.6%, 51.3%) n=7	44.4% (18.9%, 73.3%) n=9	75% (30.1%, 95.4%) n=4	66.7% (30%, 90.3%) n=6	50% (9.5%, 90.5%) n=2
Esophagus (n=27)	0% (0%, 39%) n=6	20% (3.6%, 62.4%) n=5	75% (40.9%, 92.9%) n=8	85.7% (48.7%, 97.4%) n=7	100% (20.7%, 100%) n=1
Liver and Bile Duct (n=25)	40% (11.8%, 76.9%) n-5	83.3% (43.6%, 97%) n=6	100% (67.6%, 100%) n=8	100% (56.6%, 100%) n=5	0% (0%, 79.4%) n=1
Anus (n=16)	0% (0%, 79.4%) n=1	62.5% (30.6%, 86.3%) n=8	66.7% (20.8%, 93.9%) n=3	100% (43.9%, 100%) n=3	0% (0%, 79.4%) n=1
Ovary (n=14)	0% (0%, 79.4%) n=1	0% (0%, 79.4%) n=1	85.7% (48.7%, 97.4%) n=7	66.7% (20.8%, 93.9%) n=3	100% (34.2%, 100%) n=2
Vulva (n=13)	0% (0%, 39%) n=6		66.7% (20.8%, 93.9%) n=3	100% (34.2%, 100%) n=2	50% (9.5%, 90.5%) n=2
Cervix Uteri (n=13)	100% (34.2%, 100%) n=2	66.7% (20.8%, 93.9%) n=3	100% (43.9%, 100%) n=3	100% (34.2%, 100%) n=2	33.3% (6.1%, 79.2%) n=3
Thyroid (n=13)	0% (0%, 49%) n=4	0% (0%, 49%) n=4		50% (15%, 85%) n=4	0% (0%, 79.4%) n=1
Small Intestine (n=10)		66.7% (20.8%, 93.9%) n=3	25% (4.6%, 69.9%) n=4	33.3% (6.1%, 79.2%) n=3	
Non-Hodgkin Lymphoma (n=7)	0% (0%, 79.4%) n=1		0% (0%, 65.8%) n=2	50% (15%, 85%) n=4	

Testis (n=2)	50% (9.5%, 90.5%) n=2				
Multiple Myeloma (n=1)		0% (0%, 79.4%) n=1			

MP, methylation-protein.

725 Table 4. MP-reflex classifier test set performance

Test Set	Estimate % (95% CI)	n/N
Specificity	98.5% (97.9-98.9)	2,440/2,477
Sensitivity, all cancers	55.2% (51.6-58.8)	412/746
Stage I	19.0% (14.0-25.3)	35/184
Stage II	41.2% (34.0-48.8)	68/165
Stage III	71.9% (65.0-77.9)	133/185
Stage IV	89.4% (84.1-93.1)	161/180
Unknown stage	46.9% (30.9-63.6)	15/32
Stage I, II	29.5% (25.0-34.5)	103/349
Stage I-III	44.2% (40.0-48.4)	236/534
Sensitivity-excluding breast and prostate	61.6% (57.6-65.3)	373/606
Stage I	21.9% (16.0-29.3)	32/146
Stage II	52.7% (43.5-61.8)	58/110
Stage III	75.9% (68.7-81.9)	120/158
Stage IV	90.8% (85.4-94.3)	148/163
Unknown stage	51.7% (34.4-68.6)	15/29
Stage I, II	35.2% (29.6-41.2)	90/256
Stage I-III	50.7% (45.9-55.5)	210/414
Sensitivity*	59.4% (55.1-63.6)	300/505
Sensitivity**	66.9% (61.4-71.9)	206/308

726

727 MP, methylation-protein.*sensitivity excluding cancer organ types with average-risk standard of
728 care screening (i.e., excluding breast, prostate, cervix, colon and rectum). **sensitivity for the 6
729 most aggressive cancer organ types with the shortest 5-year survival rate reported by National
730 Cancer Institute Surveillance, Epidemiology, and End Results (SEER) (i.e., pancreas,
731 esophagus, liver, lung and bronchus, stomach, and ovary).

732

733 Figure 1. MP classifier development and test cohorts



734

735 MP, methylation-protein. *One sample was excluded for both age and blood processing
736 reasons.

737

738

739

740

741

742

743

744

745 Figure 2. Testing workflow



746

747 LR, logistic regression; MP, methylation-protein.

748

749 Figure 3. a) Methylation-Protein and b) Methylation-Protein-reflex classifier schema



750

751 MP, methylation-protein.

752

753

754

755

756

757

758

759

760

761

762

763

764 Figure 4. MP classifier organ-specific performance at 98.5% specificity*



765

766 MP, methylation-protein. NHL, Non-Hodgkin Lymphoma. *Multiple Myeloma (n=1) and testicular
767 cancers (n=2) were omitted from the graph due to the small number of cases. The numbers at
768 the base of each bar represent the number of cases.

769

770

771

772

773

774

775

776

777

778 Figure 5. MP-reflex classifier development and test cohorts



779

780 MP, methylation-protein; QC, quality control.

781

782

783

784

785

786

787

788

789 Figure 6. MP and MP-reflex classifier performance comparison (breast and prostate cancers

790 excluded)*

791



792

793 MP, methylation-protein.*using MP-reflex test set cohort (746 cancers and 2,477 non-cancers).
794 The absolute change=%MP reflex sensitivity-%MP sensitivity. The relative change=%MP reflex
795 sensitivity-%MP sensitivity/%MP sensitivity.

796

797

798

799